The Secretory Shunt: A Unified Framework for Tauopathy Progression and Therapeutic Intervention
Fuente:
Zenodo
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Recurso digital |
| Lenguaje: | inglés |
| Publicado: |
Zenodo
2025
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1866901329579868160 |
|---|---|
| author | Martinez, Aaron |
| author_facet | Martinez, Aaron |
| contents | <p> </p> <p>Decades of clinical trials targeting tau aggregation and autophagy enhancement in Alzheimer's disease have yielded disappointing results. We propose that these failures stem from a fundamental misunderstanding of how neurons handle pathological tau. When autophagy is blocked by p62-tau condensate formation, neurons activate a compensatory "Secretory Shunt"—a RAB27A-mediated pathway that ejects tau-laden vesicles rather than degrading them. This mechanism explains the paradox of autophagy enhancer failures and provides a framework for patient stratification and therapeutic sequencing.</p> <p>Analysis of 2,004 human brain samples (GSE84422) reveals five key findings, all persisting after adjustment for disease stage: (1) RAB27A strongly correlates with p62/SQSTM1 (r = 0.539, p < 10⁻¹⁵⁰); (2) RAB27A inversely correlates with RAB27B (r = −0.516), confirming a non-canonical pathway; (3) RAB27A negatively correlates with synaptophysin (r = −0.357), suggesting vesicular machinery diversion; (4) RAB27A inversely correlates with MAP2 (r = −0.455), linking microtubule destabilization to Shunt activation; and (5) RAB27A inversely correlates with AQP4 (r = −0.336), suggesting glymphatic compensation failure.</p> <p>We propose a three-stage treatment protocol and identify candidate molecules for immediate testing: alpha-lipoic acid (condensate modifier), macitentan (RAB27A/ETA antagonist), and D-peptide disaggregators. Two are FDA-approved and off-patent. Methods described herein are subject to US Provisional Patent Application 63/949,234.</p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_18071910 |
| institution | Zenodo |
| language | eng |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | The Secretory Shunt: A Unified Framework for Tauopathy Progression and Therapeutic Intervention Martinez, Aaron Alzheimer Disease taupathies tau Proteins Autophagy Exosomes Sequestosome-1 Protein rab27 GTP-Binding Proteins Biomarkers Drug Therapy secretory shunt RAB27A p62-tau condensates phase separation patient stratification therapeutic sequencing alpha-lipoic acid macitentan <p> </p> <p>Decades of clinical trials targeting tau aggregation and autophagy enhancement in Alzheimer's disease have yielded disappointing results. We propose that these failures stem from a fundamental misunderstanding of how neurons handle pathological tau. When autophagy is blocked by p62-tau condensate formation, neurons activate a compensatory "Secretory Shunt"—a RAB27A-mediated pathway that ejects tau-laden vesicles rather than degrading them. This mechanism explains the paradox of autophagy enhancer failures and provides a framework for patient stratification and therapeutic sequencing.</p> <p>Analysis of 2,004 human brain samples (GSE84422) reveals five key findings, all persisting after adjustment for disease stage: (1) RAB27A strongly correlates with p62/SQSTM1 (r = 0.539, p < 10⁻¹⁵⁰); (2) RAB27A inversely correlates with RAB27B (r = −0.516), confirming a non-canonical pathway; (3) RAB27A negatively correlates with synaptophysin (r = −0.357), suggesting vesicular machinery diversion; (4) RAB27A inversely correlates with MAP2 (r = −0.455), linking microtubule destabilization to Shunt activation; and (5) RAB27A inversely correlates with AQP4 (r = −0.336), suggesting glymphatic compensation failure.</p> <p>We propose a three-stage treatment protocol and identify candidate molecules for immediate testing: alpha-lipoic acid (condensate modifier), macitentan (RAB27A/ETA antagonist), and D-peptide disaggregators. Two are FDA-approved and off-patent. Methods described herein are subject to US Provisional Patent Application 63/949,234.</p> |
| title | The Secretory Shunt: A Unified Framework for Tauopathy Progression and Therapeutic Intervention |
| topic | Alzheimer Disease taupathies tau Proteins Autophagy Exosomes Sequestosome-1 Protein rab27 GTP-Binding Proteins Biomarkers Drug Therapy secretory shunt RAB27A p62-tau condensates phase separation patient stratification therapeutic sequencing alpha-lipoic acid macitentan |
| url | https://doi.org/10.5281/zenodo.18071910 |